Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Myeloma Therapy
Research from Vanderbilt University, Department of Pediatrics in myeloma therapy provides new insights
September 3rd, 2008
New research, 'An optimized electrofusion-based protocol for generating virus-specific human monoclonal antibodies,' is the subject of a report. According to a study from the United States, "We sought to develop and optimize a hybridoma-based technology for generating human hybridomas that secrete virus-specific monoclonal antibodies for clinical diagnosis and therapy. We developed a novel electrofusion protocol for efficiently fusing Epstein-Barr virus (EBV)-transformed human B cells with myeloma partners." "We tested seven myeloma cell lines and achieved highest efficiency when the HMMA 2.5 line was used. We optimized the electrofusion process by improving cell...
Source: Vaccine Weekly (2008-09-03)
|
